share_log

Altimmune | 8-K: Current report

Altimmune | 8-K: Current report

Altimmune | 8-K：重大事件
美股sec公告 ·  06/26 07:38
Moomoo AI 已提取核心信息
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.
Altimmune，一家临床阶段的生物制药公司，宣布其首席财务官Richard Eisenstadt於2024年6月24日意外去世。公司董事会随即任命Andrew Shutterly为代理首席财务官，立即生效。Shutterly自2020年10月以来一直在Altimmune工作，此前担任企业控制器自2023年2月以来，并具有在Meso Scale Diagnostics LLC和Deloitte的会计经验。Altimmune将与Shutterly签订类似其他高管的赔偿协议。该公司还发布了一份新闻稿表示慰问，并已开始寻找永久性的CFO接任人选。Altimmune专注于开发基于多肽的治疗药物，目前正在开发针对肥胖症和非酒精性脂肪肝的pemvidutide。
Altimmune，一家临床阶段的生物制药公司，宣布其首席财务官Richard Eisenstadt於2024年6月24日意外去世。公司董事会随即任命Andrew Shutterly为代理首席财务官，立即生效。Shutterly自2020年10月以来一直在Altimmune工作，此前担任企业控制器自2023年2月以来，并具有在Meso Scale Diagnostics LLC和Deloitte的会计经验。Altimmune将与Shutterly签订类似其他高管的赔偿协议。该公司还发布了一份新闻稿表示慰问，并已开始寻找永久性的CFO接任人选。Altimmune专注于开发基于多肽的治疗药物，目前正在开发针对肥胖症和非酒精性脂肪肝的pemvidutide。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息